10 Small-Cap Biotechs with Key Catalysts for 2025 July List
https://www.tradingview.com/chart/IBB/12VGMavi-10-Small-Cap-Biotechs-with-Key-Catalysts-for-2025-July-List/
________________________________________
1. Allogene Therapeutics (NASDAQ: ALLO)
• Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission.
• Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates.
________________________________________
2. Lixte Biotechnology (NASDAQ: LIXT)
• Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025.
• Highlights: If efficacy signals emerge, could prompt partnerships or additional trials.

✅continue reading on TradingView

🚀 Syndicate Biotech Newsletter – June 2025 Edition FREE! 🧬

Do you want real biotech stock analysis, not just hype?
The Syndicate Biotech Newsletter is your edge in the world of biotech investing!

✨ What You Get:
🔹 Expert stock rankings (proprietary scoring)
🔹 Full pipeline + catalyst calendars
🔹 Insider trading & cash runway analysis
🔹 Analyst-grade insights (50+ years experience)
🔹 Transparent, actionable info – no fluff
🎁 June 2025 Edition is FREE to download!
🔥 LIMITED OFFER:
Unlock 12 months of access for just 1,000 USDT (ERC20/TRC20).
Get all future issues, exclusive rankings, and real Q&A with our analysts.
⏰ Don’t miss out—biotech moves fast, and so do the best opportunities!

[Download June 2025 Edition FREE]
https://t.me/thesyndicate001/10566
[Subscribe Now – 12 Months for 1,000 USDT]
https://t.me/PRSYNDICATE